January 21, 2022 05:16 AM ESTUpdated 01:17 PM

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Derek Graf

→ The needle on the Maraganore Meter is moving again, as John Maraganore keeps collecting more post-Alnylam roles. First, he and BeiGene co-founder Peter Ho …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Derek Graf

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

As Hal Bar­ron steals the show, there’s no off po­si­tion on the John Maraganore switch; Dan­ny Bar-Zo­har makes an­oth­er leap for­ward at Mer­ck KGaA

Senior Editor

Editor

Sign up to read this article for free.

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA